Physician profile
Ryan H Patrick
NPI 1346560026
$2,364.18
in general payments reported to CMS, 2019-2025
31 companies · $980 in 2025
The $980 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $493 · 2020: $105 · 2021: $151 · 2022: $120 · 2023: $111 · 2024: $405 · 2025: $980.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,495.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $369.07 | 2022-2025 | |
| Pfizer INC. | $292.82 | 2024-2025 | |
| Lilly USA, LLC | $170.09 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Acadia Pharmaceuticals INC | $164.64 | 2019-2025 | Nuplazid |
| Alexion Pharmaceuticals, INC. | $151.93 | 2019-2025 | Ultomiris |
| Mdd US Operations, LLC | $143.76 | 2019-2024 | Gocovri, Gocovri |
| Ge Healthcare | $136.96 | 2019-2025 | |
| Biogen, INC. | $107.95 | 2021-2025 | Vumerity, Tysabri |
| Novartis Pharmaceuticals Corporation | $102.78 | 2019-2025 | |
| Lundbeck LLC | $75.12 | 2019-2025 | Vyepti, Rexulti |
| Ucb, INC. | $74.08 | 2024-2025 | Briviact, Rystiggo, Zilbrysq |
| Argenx US, INC. | $57.88 | 2022-2025 | Vyvgart Hytrulo |
| Takeda Pharmaceuticals U.S.A., INC. | $56.43 | 2025 | Hyqvia |
| Otsuka America Pharmaceutical, INC. | $45.09 | 2025 | Rexulti |
| Eisai INC. | $42.00 | 2023-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $38.67 | 2025 | Zeposia |
| Philips North America LLC | $38.58 | 2019 | |
| Amneal Pharmaceuticals LLC | $36.71 | 2022-2023 | Rytary |
| Nevro Corp. | $32.70 | 2019 | |
| Genentech USA, INC. | $31.76 | 2019 | |
| Axsome Therapeutics, INC. | $24.95 | 2025 | Symbravo |
| Amgen INC. | $24.71 | 2019-2024 | Enbrel |
| Livanova USA, INC. | $18.83 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $17.92 | 2021 | |
| Arbor Pharmaceuticals, INC. | $17.54 | 2021 | |
| Avion Pharmaceuticals | $16.77 | 2022 | |
| Sunovion Pharmaceuticals INC. | $16.23 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $16.13 | 2022 | |
| Sumitomo Pharma America, INC. | $15.91 | 2024 | Aptiom |
| Adamas Pharmaceuticals, INC. | $13.17 | 2019 | |
| Supernus Pharmaceuticals, INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Patrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.